Navigation Links
Amgen and Peregrine Under StockCall Scrutiny: Pharma Stocks Deal with Drug Developments and Patents
Date:2/6/2013

of its revenue from Neupogen franchise. However, the drug would go off patent protection by the end of 2013 and the loss of exclusivity is expected to affect Amgen. Neupogen faces stiff competition from the companies like Novartis in the markets outside of the U.S. and these competing companies may launch their products in the U.S., causing further damage. However, the company has somewhat strong drug candidates including AMG145, a cholesterol drug candidate.

Amgen stock grew over 25 percent in the past 12 months. It also offers good dividend yield of 2.17 percent. The company is likely to increase its dividend in the future, thus offering good returns to the investors. Amgen is also growing through acquisitions as it recently completed the purchase of Icelandic company decode Genetics.

Peregrine Struggles with Cancer Drug Development

Peregrine Pharmaceuticals Inc. specializes in developing therapies for viral infections. It also develops treatments for cancers. It is currently engaged in developing treatment for non-small cell lung cancer. If successful, the company will make big fortunes as non-small cell lung cancer accounts for about 80 percent of lung cancer cases. However, the company does not have very solid track record. The drug candidate bavituximab has been controversial as it led to the stock's massive tumble in September 2012. Sign up to download the free technical analysis on Peregrine Pharmaceuticals at

http://www.StockCall.com/PPHM020613.pdf  

Peregrine is a small company with the market capitalization of less than $300 million. The stock is quite volatile as well. The company is currently looking to get past the phase II for bavituximab. Overall, the stock may be held if it is already in your portfolio. On the upside, the stock is currently trading about 50 percent below its 52-week high, thus in case of positive news on its
'/>"/>

SOURCE StockCall.com
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Amgen to Acquire Mustafa Nevzat, a Leading Privately Held Turkish Pharmaceutical Company
2. Four Californians Selected As Breakaway from Cancer® Champions To Be Honored During Amgen Tour of California
3. Amgen to Present at the Baird Growth Stock Conference
4. Amgen To Provide Testimony At FDA Stakeholder Hearing On Biosimilars
5. Amgens BiTE® Antibody Blinatumomab (AMG 103) Achieved High Rate of Complete Response in Adult Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia
6. Amgen Announces Top-Line Results Of Phase 3 Sensipar®/Mimpara® EVOLVE™ Trial
7. Amgen Completes Acquisition of Mustafa Nevzat Pharmaceuticals
8. Amgen Completes Acquisition of KAI Pharmaceuticals
9. Amgens Second Quarter 2012 Revenues Increased 13 Percent To $4.5 Billion And Adjusted Earnings Per Share (EPS) Increased 34 Percent To $1.83
10. Amgen Announces Termination Of Ganitumab Phase 3 Study For Futility In Metastatic Pancreatic Cancer
11. Amgen To Present At The Baird Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/24/2014)... -- Boston Children,s Hospital,s Global Pediatric Summit + Awards, ... "Innovation Tank" – a forum designed to give pediatric ... or product solution to a panel of acclaimed judges ... accelerate the innovation and bring it to market. ... 31, will be moderated by Daymond John ...
(Date:7/24/2014)... 24, 2014  Bruin Biometrics (BBI), a pioneer ... after two weeks of clinical briefings to over ... it gained substantial concurrence on both the clinical ... utility of BBI,s SEM Scanner. ... the respondents drawn from the European Wound Management ...
(Date:7/24/2014)... N.J. , July 24, 2014  Bayer ... III trial that evaluated a 15% foam formulation ... topical treatment of inflammatory papules and pustules of ... treatment option to complement the currently available AzA ... causing inflammatory lesions (papules and pustules) as well ...
Breaking Medicine Technology:Taking on Tomorrow to Feature "Innovation Tank" Pitch Opportunity for Aspiring Pediatric Health Care Entrepreneurs 2Taking on Tomorrow to Feature "Innovation Tank" Pitch Opportunity for Aspiring Pediatric Health Care Entrepreneurs 3Bruin Biometrics Secures Support of EU Scientific Community for its SEM Scanner Technology 2Phase III Investigational Trial of Azelaic Acid 15% Foam Meets Both Co-Primary Endpoints in Subjects with Papulopustular Rosacea 2Phase III Investigational Trial of Azelaic Acid 15% Foam Meets Both Co-Primary Endpoints in Subjects with Papulopustular Rosacea 3
... The Leukemia & Lymphoma,Society has awarded a $550,000 ... Wilmot Cancer Center at the University of Rochester Medical,Center. ... funding the first two years of the five-year program., ... will support,Dr. Friedberg,s work on a new targeted treatment ...
... Assay Submitted for FDA Clearance, SAN DIEGO, July ... and Company) (NYSE: BDX ), announced today the ... the rapid diagnosis,of patients with Clostridium difficile infection (CDI). ... simplicity and speed in one test,procedure. BD has also ...
Cached Medicine Technology:University of Rochester Researcher Named Millennium Pharmaceuticals Career Development Scholar of The Leukemia & Lymphoma Society 2BD Announces CE Marking of a New Molecular Test to Diagnose Patients with Clostridium difficile Infections 2BD Announces CE Marking of a New Molecular Test to Diagnose Patients with Clostridium difficile Infections 3
(Date:7/24/2014)... The report, “Feed Palatability Enhancers & ... (Swine, Poultry, Cattle, Pets, Aquaculture, and Others) - Global ... feed palatability enhancers & modifiers market with an analysis ... value, of types of feed flavors, sweeteners, and text ... figures spread through 275 pages and in-depth TOC on ...
(Date:7/24/2014)... increases your risk of death, but recessions decrease ... While previous studies of individuals have shown that ... mortality rate, more comprehensive studies have shown, unexpectedly, ... increase. Researchers from Drexel University and the University ... better understand these seemingly contradictory findings. , Using ...
(Date:7/24/2014)... (PRWEB) July 24, 2014 While healthcare ... in providing quality interpretation services to non-English speakers within ... down. According to Common Sense Advisory, the language ... to $2.3 billion in 2016 (1); additionally, officials at ... to shift over to video remote interpreting ...
(Date:7/24/2014)... known as neonicotinoids, were found commonly in streams ... study. This is the first broad-scale investigation of ... one of the first conducted within the United ... of insect pests, use of neonicotinoid insecticides has ... United States, particularly in the Midwest. The ...
(Date:7/24/2014)... Dr. Kwame Bawuah Edusei, a diplomat, entrepreneur, medical ... to the youth to persevere in their endeavors to ... the youth to stay away from social vices and ... will afford you the opportunity of acquiring life surviving ... in your career path.” Professionals in the fields of ...
Breaking Medicine News(10 mins):Health News:Feed Palatability Enhancers & Modifiers Market Worth $3172.6 Million by 2019 - Report by MarketsandMarkets 2Health News:Feed Palatability Enhancers & Modifiers Market Worth $3172.6 Million by 2019 - Report by MarketsandMarkets 3Health News:Feed Palatability Enhancers & Modifiers Market Worth $3172.6 Million by 2019 - Report by MarketsandMarkets 4Health News:Joblessness could kill you, but recessions could be good for your health 2Health News:Joblessness could kill you, but recessions could be good for your health 3Health News:Stratus Video Interpreting Predicts $1 Billion Market Shift to Video Remote Interpreting by 2016 as Court and Healthcare Systems Heed Cost-Effectiveness 2Health News:Stratus Video Interpreting Predicts $1 Billion Market Shift to Video Remote Interpreting by 2016 as Court and Healthcare Systems Heed Cost-Effectiveness 3Health News:Stratus Video Interpreting Predicts $1 Billion Market Shift to Video Remote Interpreting by 2016 as Court and Healthcare Systems Heed Cost-Effectiveness 4Health News:Corn & soy insecticides similar to nicotine found widespread in Midwest rivers -- USGS news 2Health News:Youth and Professionals Interact at Washington Metro Area Career Workshop Hosted by the Edusei Foundation 2
... aid in understanding ADD and more , FRIDAY, Aug. 28 ... a crowd, it appears that your "mind,s eye" acts like ... until you find the right person. , Researchers from the ... as they searched for a specific tilted, colored bar among ...
... 28 /PRNewswire-Asia/ -- Sinovac Biotech Ltd. (NYSE: ... announced today that,the Beijing Public Health Bureau has selected ... Sinovac,s seasonal influenza vaccine, for,the benefit of the citizens ... process for the purchase of flu vaccines and,corresponding services ...
... , HARBIN, China, Aug. 28 ... Medical" or "the Company") (Nasdaq: CSKI ), ... People,s Republic of China ("PRC"), today announced that the,Company,s ... Thursday,September 24, 2009 at Harbin Shen Te Hotel which ...
... ... , ... (PRWEB) August 28, 2009 -- Promising cancer research treatment breakthrough seeks funding for corroboration., ... CHAI Foundation , a small 501(c)(3) non-profit medical research organization seeking to find ...
... , TOKYO, Aug. 28 ALOKA CO., ... generation of compact color ultrasound systems. This new multi-purpose system, ... fully upgradable and easy to use. , , ... ProSound Alpha 10 and Alpha 7, the ProSound Alpha 6 ...
... , TOSU, Saga, Japan and MIAMI, Aug. ... Inc. today announced the completion of their acquisition of Noven Pharmaceuticals, ... Inc., a wholly owned subsidiary of Hisamitsu U.S., Inc., with and ... the Agreement and Plan of Merger among the companies, at the ...
Cached Medicine News:Health News:Brain May Use Its 'Mind's Eye' to Control Chaos 2Health News:Sinovac Wins Beijing Public Health Bureau's Bid to Supply Seasonal Flu Vaccine Anflu(R) to Beijing Citizens 2Health News:Sinovac Wins Beijing Public Health Bureau's Bid to Supply Seasonal Flu Vaccine Anflu(R) to Beijing Citizens 3Health News:China Sky One Medical, Inc. to Hold Annual Meeting of Shareholders on September 24, 2009 2Health News:China Sky One Medical, Inc. to Hold Annual Meeting of Shareholders on September 24, 2009 3Health News:Promising Cancer Research Treatment Breakthrough Seeks Funding for Corroboration of Results 2Health News:ALOKA Announces New ProSound Alpha Series Ultrasound System 2Health News:ALOKA Announces New ProSound Alpha Series Ultrasound System 3Health News:Hisamitsu Pharmaceutical Completes Acquisition of Noven Pharmaceuticals 2
Ideal for use with thinner casting materials such as polyester or fiberglass. Conforms to any casting material....
This lightweight cast boot features a sturdy canvas upper. The three layer EVA rocker outsole provides excellent shock absorption....
... assay for the qualitative and ... to Gliadin in human serum. ... be used as an aid ... disorders, mainly Coeliac Disease. This ...
... Myeloperoxidase IgG ELISA test system is intended ... IgG-class antibody to myeloperoxidase in human serum. ... used as an aid in the diagnosis ... elevated levels of anti-neutrophil cytoplasmic antibodies (ANCA). ...
Medicine Products: